Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Alzamend Neuro, Inc. on April 30, 2024. The report details the voting outcomes for director elections, auditor ratification, and a proposed reverse stock split, as well as the adjournment of a specific proposal regarding share issuance.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Voting Results
- Director Elections (Proposal One): Stockholders elected all eight (8) nominated directors. Vote counts varied, with "For" votes ranging from approximately 3.48 million to 3.72 million per nominee.
- Auditor Ratification (Proposal Two): Stockholders approved the ratification of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending April 30, 2024, with 5,114,481 votes "For" and 443,299 "Against".
- Reverse Stock Split (Proposal Four): Stockholders approved an amendment to the Certificate of Incorporation to effect a reverse stock split of Common Stock by a ratio of not less than one-for-two and not more than one-for-twenty, to be determined by the Board prior to April 29, 2025.
- Share Issuance Proposal (Proposal Three): This proposal, seeking approval to issue shares upon conversion of Series B Preferred Stock and exercise of warrants under a $6,000,000 Securities Purchase Agreement with Ault Lending, LLC, failed to pass due to insufficient votes.
Outlook, Management Commentary, and Contingencies
Due to the failure of Proposal Three, the Annual Meeting was adjourned to allow additional time for voting. The Adjourned Annual Meeting is scheduled to reconvene on May 13, 2024, at 12:00 p.m. Eastern Time. Stockholders of record as of March 14, 2024, may vote online during the adjournment period. The outcome of Proposal Three remains contingent on the results of the reconvened meeting.
Investor Verification Checklist
- Verify the outcome of Proposal Three at the Adjourned Annual Meeting on May 13, 2024, as it is critical for the $6,000,000 financing arrangement with Ault Lending, LLC.
- Monitor future filings for the specific reverse stock split ratio to be determined by the Board of Directors.
- Review the definitive proxy statement (Schedule 14A) filed on March 25, 2024, for detailed background on the director nominees and the financing agreement.
- Confirm the company's compliance with Nasdaq Listing Rule 5635 following the resolution of Proposal Three.